AGIO · Agios Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$31.20
+1.25 (+4.17%)
At close · Nov 3
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$1.86B
Shares
59.70M
Volume · Nov 3
684.88K
Avg daily vol (3M)
1.09M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Agios Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Agios Pharmaceuticals, Inc. (AGIO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-05
Agios Pharmaceuticals, Inc. (AGIO) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-09
Agios Pharmaceuticals, Inc. (AGIO) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-30
Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript
Confident tone
Acvesme/mitapivat commercial launch in thalassemia
Pipeline expansion through business development
Financial position and capital allocation
Revenue
$44.74M
▲ 259.3% YoY Diluted EPS
$-1.69
Gross margin
93.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Investor Update
Investor event
2026-06-13
Agios Pharmaceuticals, Inc. (AGIO) June 13, 2026 Investor Update Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Investor Update
Investor event
2026-06-13
Agios Pharmaceuticals, Inc. (AGIO) June 13, 2026 Investor Update Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Agios Pharmaceuticals, Inc. (AGIO) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Agios Pharmaceuticals, Inc. (AGIO) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Agios Pharmaceuticals, Inc. (AGIO) May 12, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Agios Pharmaceuticals, Inc. (AGIO) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-29
Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call Transcript
Confident tone
Sickle cell disease label expansion / sNDA
Tepofitinib / next-generation PK activator
Regulatory engagement with FDA
Revenue
$20.75M
▲ 137.7% YoY Diluted EPS
$-1.69
Gross margin
93.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript
Confident tone
ACVESME/Agvesme Launch in Thalassemia
Sickle Cell Disease Opportunity (mitapivat)
Lower-Risk MDS Pipeline (AG-236)
Revenue
$19.97M*
▲ 86.1% YoY Gross margin
90.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-19
Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript
Confident tone
PYRUKYND thalassemia U.S. launch
Pipeline (Tebapivat, AG-181, AG-236)
Global commercialization partnerships
Revenue
$12.88M
▲ 43.7% YoY Diluted EPS
$-1.78
▼ 111% YoY Gross margin
87.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript
Confident tone
Thalassemia PDUFA and indication expansion
Capital-efficient ex-U.S. partnerships
Financial position and capital allocation
Revenue
$12.46M
▲ 44.6% YoY Diluted EPS
$-1.93
Gross margin
86.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript
Confident tone
PYRUKYND Franchise and Commercial Expansion
Thalassemia Regulatory Review and PDUFA
Tebapivat Pipeline in MDS and Sickle Cell
Revenue
$8.73M
▲ 6.6% YoY Diluted EPS
$-1.55
Gross margin
87.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript
Confident tone
PYRUKYND franchise and commercial launches
Thalassemia regulatory progress
Pediatric PK deficiency (ACTIVATE-KIDS)
Revenue
$10.73M*
▲ 51.1% YoY Gross margin
88.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript
Confident tone
Mitapivat in thalassemia (sNDA submission and launch)
Sickle cell disease (RISE UP Phase 3)
PK deficiency (PYRUKYND commercial launch)
Revenue
$8.96M
▲ 21.2% YoY Diluted EPS
$16.22
Gross margin
91.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Agios Pharmaceuticals, Inc. (AGIO) Q2 2024 Earnings Call Transcript
Confident tone
Mitapivat in thalassemia (ENERGIZE/ENERGIZE-T)
Sickle cell disease (RISE UP)
Pediatric PK deficiency (ACTIVATE-kids T)
Revenue
$8.62M
▲ 28.4% YoY Diluted EPS
$-1.69
Gross margin
82.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Agios Pharmaceuticals, Inc. (AGIO) Q1 2024 Earnings Call Transcript
Confident tone
Mitapivat in thalassemia (ENERGIZE/ENERGIZE-T)
Ex-U.S. partnership strategy
Pipeline and clinical milestones
Revenue
$8.19M
▲ 46% YoY Diluted EPS
$-1.45
Gross margin
92.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Agios Pharmaceuticals, Inc. (AGIO) Q4 2023 Earnings Call Transcript
Confident tone
Mitapivat pipeline progress
Thalassemia opportunity
PK deficiency commercial launch
Revenue
$7.10M*
▲ 64.8% YoY Gross margin
91.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Agios Pharmaceuticals, Inc. (AGIO) Q3 2023 Earnings Call Transcript
Revenue
$7.40M
▲ 110.4% YoY Diluted EPS
$-1.64
Gross margin
91.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Agios Pharmaceuticals, Inc. (AGIO) Q2 2023 Earnings Call Transcript
Revenue
$6.71M
▲ 20.2% YoY Diluted EPS
$-1.51
Gross margin
83.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Agios Pharmaceuticals, Inc. (AGIO) Q1 2023 Earnings Call Transcript
Revenue
$5.61M
▲ 574.2% YoY Diluted EPS
$-1.47
Gross margin
90.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Agios Pharmaceuticals, Inc. (AGIO) Q4 2022 Earnings Call Transcript
Revenue
$4.31M*
Gross margin
90.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Agios Pharmaceuticals, Inc. (AGIO) Q3 2022 Earnings Call Transcript
Revenue
$3.52M
Diluted EPS
$-1.49
Gross margin
85.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Agios Pharmaceuticals, Inc. (AGIO) Q2 2022 Earnings Call Transcript
Revenue
$5.58M
Diluted EPS
$-1.68
Gross margin
92.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Agios Pharmaceuticals, Inc. (AGIO) Q1 2022 Earnings Call Transcript
Revenue
$832,000
Diluted EPS
$-1.74
▼ 106.5% YoY Gross margin
59.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Agios Pharmaceuticals, Inc. (AGIO) Q4 2021 Earnings Call Transcript
Revenue
$0*
▼ 100% YoY Diluted EPS
$-1.74
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Agios Pharmaceuticals, Inc. (AGIO) Q3 2021 Earnings Call Transcript
Revenue
$0
▼ 100% YoY Diluted EPS
$-1.56
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Agios Pharmaceuticals, Inc. (AGIO) Q2 2021 Earnings Call Transcript
Revenue
$0
▼ 100% YoY Diluted EPS
$-1.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Agios Pharmaceuticals, Inc. (AGIO) Q1 2021 Earnings Call Transcript
Revenue
$0
▼ 100% YoY Diluted EPS
$26.95
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Agios Pharmaceuticals, Inc. (AGIO) Q4 2020 Earnings Call Transcript
Revenue
$44.05M
▲ 24.3% YoY Diluted EPS
$-1.41
Gross margin
104.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Agios Pharmaceuticals, Inc. (AGIO) Q3 2020 Earnings Call Transcript
Revenue
$34.71M
▲ 33.4% YoY Diluted EPS
$-1.43
Gross margin
98.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Agios Pharmaceuticals, Inc. (AGIO) Q2 2020 Earnings Call Transcript
Revenue
$37.35M
▲ 42.4% YoY Diluted EPS
$-1.31
Gross margin
98.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Agios Pharmaceuticals, Inc. (AGIO) Q1 2020 Earnings Call Transcript
Revenue
$87.10M
▲ 188.1% YoY Diluted EPS
$-0.59
Gross margin
99.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Agios Pharmaceuticals, Inc. (AGIO) Q4 2019 Earnings Call
Revenue
$35.44M
▲ 18.1% YoY Gross margin
99.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–35 of 35 webcasts
Key facts
CIK
1439222
CUSIP
00847X104
13F (30d)
60 filings
58 filers
Visit website
Investor relations